Xeris Pharmaceuticals, Inc. (XERS): Price and Financial Metrics
XERS Stock Summary
- Xeris Pharmaceuticals Inc's stock had its IPO on June 21, 2018, making it an older stock than merely 2.68% of US equities in our set.
- With a price/sales ratio of 98.76, Xeris Pharmaceuticals Inc has a higher such ratio than 97.79% of stocks in our set.
- Revenue growth over the past 12 months for Xeris Pharmaceuticals Inc comes in at -30.94%, a number that bests only 6.09% of the US stocks we're tracking.
- Stocks that are quantitatively similar to XERS, based on their financial statements, market capitalization, and price volatility, are NWBO, QTNT, SPPI, RMBS, and KPTI.
- Visit XERS's SEC page to see the company's official filings. To visit the company's web site, go to www.xerispharma.com.
XERS Stock Price Chart More Charts
XERS Price/Volume Stats
|Current price||$4.73||52-week high||$12.98|
|Prev. close||$4.70||52-week low||$3.84|
|Day high||$4.73||Avg. volume||578,431|
|50-day MA||$6.45||Dividend yield||N/A|
|200-day MA||$9.29||Market Cap||127.69M|
Xeris Pharmaceuticals, Inc. (XERS) Company Bio
Xeris Pharmaceuticals, Inc., a specialty pharmaceutical company, develops and commercializes ready-to-use injectable and infusible drug formulations. Its proprietary XeriSol and XeriJect formulation technologies allow for the subcutaneous and intramuscular delivery of highly-concentrated, ready-to-use formulations of peptides, proteins, antibodies, and small molecules using commercially available syringes, auto-injectors, multi-dose pens, and infusion pumps. The company’s lead product candidate is glucagon rescue pen, which has completed Phase III clinical trials for the treatment of severe hypoglycemia, a potentially life-threatening condition in people with diabetes. Its product candidates also comprise self-administered glucagon that is in Phase IIa clinical trials for the treatment of post-bariatric hypoglycemia; continuous glucagon, which is in Phase II clinical trials for the treatment of congenital hyperinsulinism; continuous glucagon that is in Phase IIa clinical trials for the treatment of hypoglycemia-associated autonomic failure; self-administered glucagon, which is in Phase IIa clinical trials for the treatment of exercise-induced hypoglycemia; and ready-to-use glucagon that is in Phase II clinical trials for use in a bi-hormonal artificial pancreas closed-loop systems. The company’s preclinical programs include ready-to-use diazepam, a ready-to-use diazepam formulation for the treatment of ARS in patients with epilepsy; and pram-insulin, a ready-to-use fixed dose combination of insulin and pramlintide. It serves patients, caregivers, and health practitioners. The company was founded in 2005 and is based in Chicago, Illinois.